

Dear Friends and Collaborators of Protagen

it has been a while since our last newsletter. Going forward we will regularly update you again on developments at Protagen, however in a new, fresher, more colorful format and we hope that you like it. The new website launched in March was the first step to introduce the new corporate design underscoring the focus on autoimmune diseases and novel diagnostic products and technologies. This is an ongoing process and we are striving to continuously improve our webpage and corporate communication and are looking forward to receiving any feedback you may have.



Protagen goes US



Avi Dukler joined in May and will support our business development with a special focus on the US and American Markets. He represents Protagen in its new Office in the Los Angeles area. Avi was formerly CEO of Glycominds and has a wealth of experience in autoimmune diseases and autoantibody diagnostic having overseen the launch of a CE marked MS test as well as setting up a CLIA lab.

Conference Attendance



This year's *biannual Congress on Autoimmunity* took place in Nice/France.

Protagen presentations on current developments of novel markers to improve diagnostics in RA, SLE and SSs were well acknowledged. The **EULAR congress** in Paris allowed for several meetings with existing and potential collaboration partners and gave proof for the SeroTag® concept, i.e. the quest for novel markers and technologies for more efficient drug development in Autoimmune Diseases.

Corporate News & PR



EY (Ernst & Young) recognized the unique business model to support clinical drug development in autoimmune diseases, and invited Protagen to contribute to the Biotechnology Report 2014 by explaining the concept for companion diagnostic development parallel to clinical studies. **transkript**, the voice of Biotechnology in Germany, Switzerland and Austria, took up the same topic and featured Protagen in its May issue. Both articles can be downloaded [here](#).

QUARTERLY UPDATE

In our quest of adding a new dimension to the world of diagnostics which have made significant progress in our own assay development with a first RUO product launch expected in July...so watch this space. The collaboration with SuppreMol was successfully finalized in April and next steps are under negotiation. The Pfizer collaboration works smoothly and progress will be reported on a continuous basis.

NEWS & FINALLY

Clinical Drug Development of Novel Compound in Autoimmune Diseases

Protagen announced today that a collaboration agreement with Pfizer Inc. has been signed. Under the collaboration, Protagen will use its proprietary SeroTag® process to attempt to discover prediction or patient stratification markers for a novel drug being developed by Pfizer.

Protagen launches major rebrand

Protagen AG has recently undergone a total rebrand and today unveiled its new website and communications materials. The novel design underscores its mission to improve the sensitivity and specificity of autoimmune diagnostics and drives more effective personalized treatment strategies.

Finally

Here we will update you with a news piece from Dortmund in the Future.

